A Systematic Review and Meta-analysis of the Impact of Local Therapies on Local Event Suppression in Metastatic Hormone-sensitive Prostate Cancer
-
Published:2024-04
Issue:
Volume:
Page:
-
ISSN:2588-9311
-
Container-title:European Urology Oncology
-
language:en
-
Short-container-title:European Urology Oncology
Author:
Tsuboi IchiroORCID, Matsukawa Akihiro, Kardoust Parizi Mehdi, Klemm Jakob, Mancon Stefano, Chiujdea Sever, Fazekas Tamás, Miszczyk Marcin, Laukhtina Ekaterina, Kawada Tatsushi, Katayama Satoshi, Iwata Takehiro, Bekku Kensuke, Karakiewicz Pierre, Wada Koichiro, Rouprêt Morgan, Araki Motoo, Shariat Shahrokh F.
Reference23 articles.
1. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer;Smith;N Engl J Med,2022 2. Apalutamide in patients with metastatic castration-sensitive prostate cancer: final survival analysis of the randomized, double-blind, phase III TITAN study;Chi;J Clin Oncol,2021 3. Enzalutamide with standard first-line therapy in metastatic prostate cancer;Davis;N Engl J Med,2019 4. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer;Fizazi;N Engl J Med,2017 5. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial;James;Lancet,2016
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|